Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > pregnancy

: Limited data; avoid

or None

Use the filters below to narrow your results.

None (10)

None (237)

Other values:

Research material (131) · Classic Psychedelic (69) · Stimulant (43) · Opioid (31) · Sedative-Hypnotic (29) · Tryptamine (26) · Phenethylamine (25) · Botanical (23) · Benzodiazepine (22) · Anticonvulsant (19) · Dissociative (19) · Plant Medicine (18) · Analgesic (17) · Antidepressant (17) · Antipsychotic (17) · Antiparkinsonian (16) · Empathogen (16) · Neuroleptic (16) · Cathinone (14) · Nootropic (13)

Other values:

5-HT2A agonist (27) · GABAA positive allosteric modulator (22) · None (20) · Monoamine releasing agent (11) · CB1/CB2 agonist (7) · Potent mu-opioid receptor agonist (6) · Sodium channel blocker (6) · Dopamine/norepinephrine reuptake inhibitor (5) · GABAA potentiator; NMDA antagonist (5) · Phenothiazine D2 antagonist (5) · Potent 5-HT2A agonist (5) · 5-HT1B/1D agonist (4) · LSD analogue; 5-HT2A agonist (4) · Mu-opioid receptor agonist (4) · Muscarinic receptor antagonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Selective norepinephrine reuptake inhibitor (4)

None (414) · 0.5–1 oz (10–30 g) ground for psychoactive effect; far smaller for culinary use (1) · 1 tablet (dextromethorphan 45 mg / bupropion 105 mg) PO daily × 3 days, then increase to 1 tablet BID (1) · 1-2 tablets (15-60 mg codeine, 300-600 mg acetaminophen) PO every 4-6 hours as needed (1) · 10 mg (one spray) intranasally in one nostril (1) · 10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 10 mg PO once daily; titrate to 20 mg/day after 1-2 weeks if needed (1) · 10-40 mg PO daily depending on hyperthyroidism severity; titrate by clinical and biochemical response (target TSH/free T4) (1) · 100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) · 100 mg PO BID; rickettsial 200 mg/d; doxy-PEP 200 mg within 72 hours after condomless sex (1) · 12.5-25 mg PO once daily (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) · 34 mg PO once daily (1) · 4-8 mg PO or IV every 8 hours as needed; 16 mg single dose preoperatively for PONV prevention (1) · 40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1) · 5 mg PO at bedtime; may increase to 10 mg if inadequate (1) · 70 mg SC monthly; may increase to 140 mg monthly (1) · A ''marduuf'' bundle (~50 g fresh leaves) chewed over a couple of hours (1) · A measured pour of absinthe diluted 5:1 with cold water over sugar (the louche ritual) (1) · Antenatal: Celestone Soluspan 12 mg IM q24h × 2 doses; topical: pea-sized amount BID; intra-articular varies by joint (1) · HRT cyclic: 200 mg PO HS days 1-12 of each month; continuous: 100 mg PO daily; ART luteal support 100 mg vaginal TID or 90 mg gel daily (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) · No current medical indication. Historical anesthetic dose 0.25 mg/kg IV (Sernyl). (1) · NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1) · One cup (~40–60 mg caffeine; about half of brewed coffee) (1) · Ozempic: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000245-QINU`"' · Wegovy: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000246-QINU`"' · Rybelsus: 3 mg PO daily × 30 d'"`UNIQ--ref-00000247-QINU`"' (1) · Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses (1) · Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice (1) · Vulvovaginal: 150 mg PO single dose; oropharyngeal: 200 mg PO day 1, then 100 mg daily ×14 days; invasive candidiasis: 800 mg load, then 400 mg PO/IV daily; cryptococcal meningitis: 400-800 mg/d (1)

None (398)

Other values:

None (418) · 10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID (1) · 10 mg per 24 h (1) · 10 mg/d (1) · 140 mg/month (1) · 2 mg/wk SC (Ozempic)'"`UNIQ--ref-0000024B-QINU`"' · 2.4 mg/wk SC (Wegovy)'"`UNIQ--ref-0000024C-QINU`"' · 14 mg PO daily (Rybelsus)'"`UNIQ--ref-0000024D-QINU`"' (1) · 2 tablets/day (dextromethorphan 90 mg / bupropion 210 mg) (1) · 20 mg/d (1) · 20 mg/day (adult); 10 mg/day in elderly and in hepatic impairment (1) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 300 mg/quarter (1) · 34 mg/d (1) · 40 mg every week (selected indications); otherwise 40 mg every other week (1) · 50 mg/d (1) · 50 mg/d (hypertension); up to 200 mg/d (edema) (1) · 60 mg/d typical (1) · 675 mg/quarter (1) · 800 mg/d (severe invasive disease) (1) · Acetaminophen 4 g/d absolute; codeine 240-360 mg/d typical practical limit (1) · Indication-dependent; 200-400 mg/d oral typical (1) · Indication-specific (1) · N/A (no current medical indication) (1) · No fixed maximum; titrated to INR target (1) · Single doses ≤16 mg (FDA 2012 advisory withdrew the 32 mg single IV dose for QT-prolongation risk); 24-32 mg/d divided (1) · Topical: nightly; oral APL: 45 mg/m²/d (1) · ~200 mg/d for most indications; higher doses for severe infections (1)

None (398) · buccal); refined cocaine has its own profile (1) · IA (1) · IM (3) · inhalation (2) · Inhalation (vaporized) (1) · insufflated (1) · intramuscular (1) · Intranasal (1) · Intravenous infusion (1) · IV (4) · IV (rarely used; same dose) (1) · on empty stomach with ≤120 mL water (1) · Oral (31) · oral (APL only) (1) · Oral (buccal absorption) (1) · Oral (buccal) (1) · Oral (leaf (1) · Oral (with MAOI) (2) · smoked (1) · smoked (extracted DMT) (1) · Subcutaneous (4) · Subcutaneous (abdomen (1) · thigh (1) · topical (3) · upper arm)'"`UNIQ--ref-0000024E-QINU`"' · Oral (Rybelsus only (1) · vaginal (1) · ≥30 min before any food/drink/other oral medicine)'"`UNIQ--ref-0000024F-QINU`"' (1)

None (414) · 15–30 min (2) · 30 minutes PO; minutes IV (1) · 30-60 minutes (1) · Anticoagulant effect at 24-72 hours; full INR effect 5-7 days (1) · Antidepressant effect emerges over 1-2 weeks; full clinical effect 4-6 weeks (1) · Benefit over weeks of dosing (1) · Biochemical improvement within 2-4 weeks; full euthyroid state 6-12 weeks (1) · Clinical improvement within 24-72 hours (1) · Diuresis at 2 hours; antihypertensive effect within days, max at 3-4 weeks (1) · Effect demonstrated within 24 hours in some patients (1) · Glycemic effect within days;<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> full weight effect over months'"`UNIQ--ref-00000250-QINU`"' (1) · Hours (2) · Onset of preventive effect over weeks; some patients respond after first dose (1) · Over weeks (2) · Pain relief reported within 15 min in trials (1) · Peak anticoagulant effect 3-4 hours (1) · Seconds (1) · Sedation/dizziness within hours of oral dose; endometrial effects over days (1) · Significant antidepressant response by week 1 in trials (faster than monoaminergic antidepressants which take 4-6 weeks) (1) · Slow, 2–6 h (1) · Smoked 2-5 min; insufflated 5-15 min; oral 30-60 min; IV / IM ~5-15 min (1) · Symptomatic effect within weeks; full response by 12-24 weeks (1) · Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days (1) · ~30 min (3)

None (413) · 12 hours (2) · 12–24 h or longer (1) · 2 weeks per dose (1) · 2-5 days after stopping (factor II resynthesis-limited) (1) · 24 hours (2) · 24 hours (once-daily dosing) (1) · 2–4 h (1) · 3-month dosing interval (1) · 3–4 h (1) · 4-12 hours (1) · 4-6 hours (1) · 4-8 hours typical; longer at high doses; residual cognitive and perceptual effects up to 48 hours (1) · 6-12 hours (1) · About 20 minutes (1) · Biologic 36-54 hours (long-acting) (1) · Daily dosing (1) · Monthly dosing (2) · Monthly or quarterly dosing (1) · N/A (1) · Oral: 8-12 hours; vaginal: 24+ hours; IM: days (1) · Sustained with twice-daily dosing (1) · ~15 min (1) · ~48 h sustained pain freedom in responders (1) · ~7 days (weekly SC dosing)'"`UNIQ--ref-00000251-QINU`"' · ~24 h (oral)'"`UNIQ--ref-00000252-QINU`"' (1) · ~7-8 hours (3)

None (416) · 16-22 hours'"`UNIQ--ref-0000047D-QINU`"' (1) · 27-32 hours'"`UNIQ--ref-00000026-QINU`"' (1) · 3-6 hours (longer in hepatic impairment)'"`UNIQ--ref-00000378-QINU`"' (1) · 36-42 hours (R/S enantiomers differ; S-warfarin is 2-5× more potent and cleared by CYP2C9)'"`UNIQ--ref-00000705-QINU`"' (1) · 6-15 hours'"`UNIQ--ref-0000013E-QINU`"' (1) · 9–12 minutes (intravenous) (1) · Codeine 2.5-3.5 hours; acetaminophen 1-3 hours'"`UNIQ--ref-00001517-QINU`"' (1) · Dextromethorphan ~22 h (when CYP2D6 inhibited); bupropion ~21 h (1) · Highly variable, 7-46 hours (mean ~21 h); lipophilic deposition in fat with delayed re-release contributes to wide range'"`UNIQ--ref-00000065-QINU`"' (1) · Plasma ~5 hours; biologic ~36-54 hours'"`UNIQ--ref-0000101A-QINU`"' (1) · ~0.5-2 hours (oral)'"`UNIQ--ref-00000BA3-QINU`"' (1) · ~12 hours (1) · ~12 hours'"`UNIQ--ref-000001FB-QINU`"' (1) · ~14 days'"`UNIQ--ref-00001103-QINU`"' (1) · ~165 hours (~1 week), among the longest of any GLP-1 RA'"`UNIQ--ref-00000253-QINU`"' (1) · ~17-19 hours (longer than daridorexant) (1) · ~27 days (2) · ~28 days (1) · ~30 hours (long, supports once-daily dosing and substantial drug-interaction window after discontinuation)'"`UNIQ--ref-00000A47-QINU`"' (1) · ~31 days (1) · ~4-6 hours (plasma); intrathyroidal accumulation gives a much longer functional duration'"`UNIQ--ref-00000ED3-QINU`"' (1) · ~5 h (caffeine) (1) · ~5-20 hours (oral micronized; highly variable)'"`UNIQ--ref-00000726-QINU`"' (1) · ~57 hours (parent), ~200 h (active metabolite) (1) · ~6.6 h (1) · ~8 hours (shorter than suvorexant and lemborexant) (1)

None (418) · 100% (IV) (1) · 65-75% (oral)'"`UNIQ--ref-0000013F-QINU`"' (1) · >90% (oral; not affected by food or gastric pH — a major practical advantage over itraconazole)'"`UNIQ--ref-00000A48-QINU`"' (1) · Codeine ~60% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001518-QINU`"' (1) · Not characterized; oral dosing once daily (1) · Not formally characterized for the combination (1) · Not formally established (1) · Not formally established (high SC) (1) · Oral ~70%; depot IM provides sustained release over weeks'"`UNIQ--ref-0000101B-QINU`"' (1) · Oral: very low (extensive first-pass); micronization improves uptake somewhat. Vaginal: high local effect with lower systemic levels (first-uterine-pass concentration)'"`UNIQ--ref-00000727-QINU`"' (1) · SC ~89%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> · Oral ~0.4–1% (SNAC-enhanced)'"`UNIQ--ref-00000254-QINU`"' (1) · Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"' (1) · ~100% (oral)'"`UNIQ--ref-00000706-QINU`"' (1) · ~44% (1) · ~5% intranasal (1) · ~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1) · ~60% (oral)'"`UNIQ--ref-00000379-QINU`"' (1) · ~62% (1) · ~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' (1) · ~72% oral; ~85% smoked'"`UNIQ--ref-00000066-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) · ~82% (1) · ~82% SC (1) · ~93% (oral)'"`UNIQ--ref-00000ED4-QINU`"' (1) · ~95% (oral; reduced by dairy, antacids, iron via divalent-cation chelation, though less than for tetracycline itself)'"`UNIQ--ref-0000047E-QINU`"' (1)

None (413) · 5-MeO-DMT is Schedule I in US (since 2011); the toad itself is protected in several southwestern states (1) · Currently legal in most jurisdictions with thujone limits (1) · Leaves legal in Bolivia, Peru, Colombia; cocaine internationally controlled (1) · Plant unrestricted; pharmaceutical atropine Rx-only (1) · Rx (6) · Rx, Schedule IV (US) (3) · Rx-only;'"`UNIQ--ref-00000256-QINU`"' not a controlled substance (1) · Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1) · Schedule I in US since 1993 (despite traditional use elsewhere); legal in Ethiopia, Kenya, Yemen, Somalia, Djibouti (1) · [[USLegal:DEA Schedule II|Schedule II]] controlled substance in US (rescheduled from Schedule III in 1978). No accepted medical use. UN Convention on Psychotropic Substances Schedule II internationally.'"`UNIQ--ref-00000067-QINU`"' (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (10) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000028-QINU`"' (1) · [[USLegal:Schedule III|Schedule III controlled substance]] in US. '''Contraindicated in children <12''' for any indication and in any age post-tonsillectomy/adenoidectomy (FDA 2017 black-box advisory)'"`UNIQ--ref-00001519-QINU`"' (1)

1

2

3

4

5

6

7

A

B

C

D

E

F

G

H

I

J